comparemela.com

Latest Breaking News On - Preludedx - Page 1 : comparemela.com

PreludeDx Welcomes Dr Pat Whitworth as Chief Medical Officer to Drive Expansion of Precision Diagnostics

/PRNewswire/ Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced the appointment of Dr. Pat.

United statesAndrew wadePat whitworthDan forcheChris emeryAptitude healthResearch committeeUniversity of louisvilleNational cancer institutePrnewswire prelude corporation preludedxNational top doctorMd anderson cancer centerNashville breast centerUniversity of california san franciscoUniversity of tennesseePrelude corporation

PreludeDx™ Presents New Data Demonstrating Utility of DCISionRT® to De-escalate Radiation Therapy for Women with DCIS

/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in precision diagnostics for early-stage breast cancer, presented data on the use of DCISionRT® to.

United statesAndrew wadeCory dunnDan forcheJulie margenthalerWashington university school of medicineSiteman cancer centerUniversity of california san franciscoPrnewswire prelude corporation preludedxPrelude corporationOrlando world center marriottNational cancer instituteAmerican societyBreast surgeonsAnnual meetingOrlando world center

PreludeDx™ to Present Data in DCIS and Stage I, II Early Breast Cancer at the 2024 Miami Breast Cancer Conference

/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that.

Cleveland clinicUnited statesMiami beachFranka viciniTroy bremerAndrew wadeChirags shahDan forcheCory dunnPrelude corporation preludedxNational cancer instituteTaussig cancer instituteUniversity of california san franciscoDepartment of radiation oncologyPrelude corporationBreast cancer conference

PreludeDx to Present Data for a Novel Molecular

PreludeDx to Present Data for a Novel Molecular Biosignature to Predict Radiation Therapy Benefit in Early-Stage Invasive Breast Cancer at the 2023 SABCS.

United statesSan antonioAndrew wadeCory dunnPrelude corporationHenryb gonzalez convention centerUniversity of california san franciscoPrelude corporation preludedxAntonio breast cancer symposiumConvention centerNovel biosignaturePredict radiation therapy responseEarly stage invasive breast cancer treatedBreast conserving surgeryAbout preludedxCalifornia san francisco

PreludeDx™ to Present Multiple Presentations at the 2023

PreludeDx today announced that data will be presented in two separate poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS)..

United statesSan antonioCory dunnYvonne zissiadisTroy bremerDan forcheAndrew wadeHenryb gonzalez convention centerUniversity of california san franciscoNational cancer institutePrelude corporationPrelude corporation preludedxAntonio breast cancer symposiumConvention centerNovel biosignaturePredict radiation therapy response

vimarsana © 2020. All Rights Reserved.